tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 145 are a BUY (96.67%), 4 are a HOLD (2.67%), 1 are a SELL (0.67%).
Analyst Chad Messer, currently employed carries an average stock price target met ratio of 47.71% that have a potential upside of 49.08% achieved within 266 days. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 261 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on GMDA, Gamida Cell Ltd at 20-Apr-2023.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$53
$-0.78 (-1.45%)
$51
16 days ago
(01-Nov-2024)
6/6 (100%)
$8.13 (18.12%)
477
Buy
$56
$2.22 (4.13%)
$37
1 months 21 days ago
(27-Sep-2024)
9/12 (75%)
$10.39 (22.78%)
227
Hold
$46
$-7.78 (-14.47%)
$30
5 months 4 days ago
(13-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
Hold
$53
$-0.78 (-1.45%)
$33
5 months 13 days ago
(04-Jun-2024)
8/8 (100%)
$5.65 (11.93%)
164
Buy
$42
$-11.78 (-21.90%)
$67
1 years 4 months 21 days ago
(27-Jun-2023)
6/12 (50%)
$13.87 (49.31%)
234
What Year was the first public recommendation made by Chad Messer?
